123 results about "Myasthenias" patented technology

The invention relates to the technical field of intelligent medical auxiliary diagnosis and neural function automatic evaluation, in particular to an NIHSS score automatic evaluation system for a stroke patient. Comprising a multi-mode induction and perception unit which is used as a front-end data entry and is used for collecting patient response in real time to generate a video stream containing depth and color information and a synchronous audio stream; the dynamic reference calibration unit is used for extracting kinematic characteristics to construct an individualized nerve reference template; the neural motion spectrum decomposition unit is used for generating a spectrum pathological feature vector for distinguishing myasthenia and ataxia; the opposite-side image rejection analysis unit is used for generating compensation and driving confidence for representing a real nerve driving intention; the cross-modal reflection analysis unit is used for generating a sensory pathway integrity index according to the nerve conduction velocity difference; and the collaborative scoring decision engine is used for mapping the multi-modal features into standardized NIHSS scores. According to the method, the interference of age and basic physique on scoring is effectively eliminated, and a high-precision comparison reference can be provided for subsequent abnormal judgment of the affected side.

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase (“BTK”) inhibitors, for treatment of patients with MG or MS.

The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody.

Provided is a circular RNA encoding CARs and the use thereof to create immune cells that target specific diseases, e. g., lymphoma, multiple myeloma and leukemia and auntoimmune diseases, such as systemic lupus erythematousus, lupus nephritis and myasthenia gravis.

The invention discloses an active constant-speed treatment and training method for patients with neurodegenerative diseases and myasthenia, and the method comprises the steps: promoting nerve remodeling through active constant-speed training, enabling the patients to use active constant-speed training equipment, and adjusting the training speed, the angle range and the impedance torque. The device activates a specific muscle group in a safe and controllable environment through an adaptive impedance training technology, gradually enhances training impedance to improve muscle strength, enhances muscle contraction efficiency through targeted training, promotes neural pathway reconstruction and improves nerve-muscle cooperative control ability, and thus achieves neural function recovery and improvement. Therefore, drug therapy provides neuroprotection and muscle function support for a patient, active constant-speed training further promotes the rehabilitation progress through accurate control and real-time feedback, and meanwhile, the flexibility and individuation of training are improved through the multi-mode man-machine interaction and cloud remote guidance functions, so that the rehabilitation effect of the patient is improved. And the treatment effect and life quality of patients with neurodegenerative diseases and myasthenia are improved.

Provided are methods for clinical treatment of generalized myasthenia gravis (gMG) using an anti-C5 antibody or antigen binding fragment thereof.

The application provides a cell fixing solution for a myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) and a product and application thereof, and relates to the technical field of in-vitro detection. The cell fixing solution provided by the application is composed of polyoxymethylene, formaldehyde, acetic acid, raffinose and a buffer solution, can effectively fix the cell morphology, maximally retains the natural spatial conformation and antigen epitope integrity of myasthenia gravis related antigens AChR, Titin, RyR1, MuSK and LRP4, reduces the problems of antigen denaturation, epitope shielding and protein loss in the fixing process, can efficiently and accurately realize the synchronous joint detection of various specific antibodies, and the myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) prepared by the application has stable detection results, and has important clinical application value and industrial popularization prospect.

This application discloses the use of a biomarker in the preparation of a product for the treatment and prediction of myasthenia gravis, wherein the biomarker is one or more of OSM, CASP-8, TRAIL, TGF-α, FLT3L, IFN-γ, IL-7, and AXIN1. Through multi-omics combined analysis, this application explores the dynamic changes and molecular mechanisms of immune-inflammatory-related proteins after complement inhibition from the dual dimensions of gene transcription and protein expression, and finds a comprehensive biomarker that can systematically evaluate the dynamics of symptom improvement and the degree of disease stability, with the advantages of accurately guiding treatment adjustments and predicting disease outcomes.

The present disclosure provides methods for treating patients with myasthenia gravis, particularly patients who have been diagnosed of myasthenia gravis within 2 years.

This invention relates to the field of medical data mining technology, specifically to a system for assessing eye muscle fatigue in myasthenia gravis based on infrared thermal imaging. First, the degree of blood circulation impairment is determined based on the temperature changes of pixels in various directions within a speckled region. Then, based on the number of speckled regions and the concentration of hot spots, a speckled region influence value reflecting local blood circulation and metabolic abnormalities is determined. Next, combining the degree of blood circulation impairment, the speckled region influence value, and the speckled region distribution, a comprehensive reference degree of eye muscle fatigue is determined. Furthermore, considering the distribution of speckled regions under the influence of grease, the degree of blood circulation impairment, and the characteristic that the reference degree of eye muscle fatigue typically does not change, a corresponding grease influence value is determined. Thus, combining the reference degree of eye muscle fatigue and the grease influence value allows for a more accurate determination of the eye muscle fatigue assessment value, resulting in better assessment of eye muscle fatigue in myasthenia gravis based on this value.

The invention discloses a benzofuran glycoside compound as well as a separation and extraction method, a pharmaceutical composition and application thereof. The compound 1 is separated from an eupatorium chinense extract. And separating and purifying chemical components of the n-butyl alcohol part of the eupatorium chinense root to obtain the benzofuran compound. The inhibition activity of target cyclooxygenase-2 of inflammatory related diseases of all the separated compounds 1 is tested, and the compounds 1 have good inhibition activity on COX-2 enzyme and have good binding energy with target protein. In addition, the compound also has a good NLRP3-related inhibition effect, can be independently used or combined with other medicines to regulate NLRP3-related proteins, and is used for treating NLRP3-related mediated diseases and / or diseases and preparing medicines for preventing or treating the diseases or diseases. The compound 1 also has a good inhibition effect on acetylcholin esterase, and can be used for treating Alzheimer's disease, myasthenia gravis, Parkinson's disease and other diseases.

The utility model relates to the field of rehabilitation training instruments, in particular to a rehabilitation device for myasthenia patients, a rehabilitation part comprises a shell, a groove is formed in the shell, a driving motor is arranged in the shell, the output end of the driving motor is connected with a lifting threaded rod, and the top of the lifting threaded rod is movably connected with the top of the inner wall of the groove; a lifting block is arranged on the surface of the lifting threaded rod and located in the groove, a baffle is arranged on the front face of the lifting block, the front face of the baffle extends out of the groove, a clamping groove is formed in the front face of the baffle, a clamping column is arranged on the inner wall of the clamping groove, a rotating plate is movably connected to the surface of the clamping column, and fixing rollers are arranged on the two sides of the rotating plate. A driving motor can be started to enable a lifting threaded rod to rotate, then a lifting block drives a baffle and a connecting structure of the baffle to conduct height change till the position where a fixed roller is located is matched with the height of a patient sitting on the seat, and when the fixed roller can be arranged to be suitable for upper and lower limb exercise actions, a rotating plate can be pushed to rotate.

The present invention provides for a novel method for the detection of the presence of myasthenia gravis in a subject, by means of detecting the presence of fibrinogen in serum generated from the blood of the patient. Further novel means for stabilizing the fibrinogen, for the purposes of interrogation of the sample, are provided.

The present invention relates to a novel complement C5-binding antibody and a use thereof. The complement C5-binding antibody according to the present invention can significantly inhibit complement C5 activity by targeting the MG1 domain of the beta chain of complement C5, and thus can be used for preventing or treating various complement-related diseases including myasthenia gravis, age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria.

The invention discloses application of a metabolic marker in preparation of an eye myasthenia gravis diagnostic reagent, and belongs to the technical field of biological medicine. According to the constructed OMG evaluation model, the AUROC for distinguishing an OMG patient from a healthy sample is 0.920 (95% CI: 0.874-0.965), which shows that the overall discrimination ability is high; according to the present invention, the detection results show that the average precision is 0.956 (95% CI: 0.922-0.990), the sensitivity is 0.816 (95% CI: 0.736-0.901), the specificity is 0.940 (95% CI: 0.870-1.000), and the precision is 0.959 (95% CI: 0.909-1.000); the model is excellent in overall distinguishing ability and prediction accuracy, and OMG patients can be effectively identified.

This invention relates to the field of image edge detection technology, specifically to an eyelid detection system for assessing the orbicularis oculi muscle movement function in patients with myasthenia gravis. The system includes a video frame acquisition module, an iris morphology reconstruction module, an interference level acquisition module, a gradient map correction module, and an eyelid edge detection module. By acquiring video frame data of the patient's eyes, the system corrects iris deformation in the iris region of the target image frame corresponding to eye movement. Based on the corrected iris region, the system analyzes the interference of iris morphology on eyelid edge detection, determines the degree of iris deformation interference, and then corrects the gradient values ​​of gradient points in the same area corresponding to the corrected iris region in the gradient map of the target image frame during eye movement, obtaining a corrected gradient map. Based on the corrected gradient map, the system determines the patient's eyelid edge detection result. This invention effectively improves the accuracy of eyelid edge detection for patients.

The invention relates to the technical field of biomedicine, discloses application of an HGF receptor inhibitor in preparation of a medicine for treating / preventing myasthenia gravis, provides a novel treatment medicine for the myasthenia gravis, and innovatively discovers that the HGF receptor inhibitor can be used for treating / preventing the myasthenia gravis by regulating body inflammation and relieving the progress, clinical phenotype and pathological phenotype of MG diseases. The myasthenia gravis disease is treated.

The invention belongs to the technical field of traditional Chinese medicine compositions, and discloses a traditional Chinese medicine composition suitable for myasthenia patients and a preparation method and application thereof. The traditional Chinese medicine is prepared from the following traditional Chinese medicine raw materials in parts by weight: 15-60 parts of astragalus membranaceus, 15-60 parts of humulus scandens, 10-30 parts of philippine flemingia root, 10-30 parts of beautiful millettia root, 10-20 parts of codonopsis pilosula, 5-15 parts of poria cocos, 5-15 parts of bighead atractylodes rhizome, 3-10 parts of liquorice, 5-15 parts of rhizoma cimicifugae, 5-15 parts of radix bupleuri, 5-15 parts of radix angelicae sinensis and 3-10 parts of pericarpium citri reticulatae. The invention solves the technical problems that the existing muscle-strengthening medicine has a limited improvement effect on symptoms such as blepharoptosis, dysphagia, weakness of limbs, soreness and weakness of waist and knees, unstable standing, difficulty in walking and the like caused by deficiency of spleen and stomach and deficiency of lower jiao kidney essence, and is not suitable for patients with fire excess from yin deficiency, liver-yang hyperactivity constitution and dampness stagnation.

The application discloses a kind of myasthenia gravis dynamic diagnosis and treatment path optimization method and system based on multimodal fusion, the method includes: the multimodal data of myasthenia gravis patient is collected, and its feature extraction and enhancement are carried out to obtain multimodal feature;Based on multimodal feature, construct three-dimensional dynamic feature matrix and carry out cross-modal fusion, obtain target fusion feature;Target fusion feature is used to train multi-task depth network model, and the diagnosis and treatment path optimization model is obtained;According to preset interval, data is dynamically collected and input model, and diagnosis and treatment evaluation result is output to realize diagnosis and treatment path dynamic optimization.Due to the application, through multimodal fusion and dynamic optimization mechanism, break the limitation of traditional static path diagnosis and treatment, effectively excavate patient multidimensional disease characteristics, improve diagnosis and treatment evaluation accuracy, realize diagnosis and treatment path dynamic optimization, effectively reduce unreasonable diagnosis and treatment behavior, reduce diagnosis and treatment cost, improve efficiency, provide intelligent support for clinic, improve diagnosis and treatment effect.

The present application relates to a kind of tetrahydropyrrolizino [2, 3-c] quinoline alkaloid compound and derivative with novel structure and preparation method and purposes thereof.The new compound bungeanoline G provided in the present application is extracted and separated from Papaveraceae Corydalis bungeana Turcz.The present application also proposes a method for artificially synthesizing bungeanoline G, and a series of derivatives of bungeanoline G are prepared.Biological activity experiments show that the compounds have acetylcholinesterase and butyrylcholinesterase inhibitory activity, and can be applied in the preparation of drugs for treating or improving various neurodegenerative diseases such as Alzheimer's disease, vascular dementia, myasthenia gravis and the like.

The invention relates to a medicine for treating myasthenia gravis and application thereof, and belongs to the technical field of medical biology. The invention relates to a medicament for treating myasthenia gravis (MG), which is characterized in that the medicament contains a Bruton's tyrosine kinase (BTK) inhibitor Pirtobrutinib, and the medicament can be used for treating myasthenia gravis (MG). The Pirtobrutinib is a third generation of BTK (brutinib) inhibitor with high selectivity and a non-covalent (reversible) binding mode. The Pirtobrutinib can be used for effectively treating the MG, and meanwhile, the serious safety defect of similar medicines in the prior art can be avoided.

The utility model discloses a myasthenia gravis rehabilitation exercise device, which relates to the technical field of medical instruments and comprises a bottom plate, supports are mounted on two sides of the top of the bottom plate, a tray is movably connected between the two supports, one end of the tray is open, and brackets are fixedly connected to two sides of one end of the tray. Connecting plates are fixedly installed at the two ends of the inner side of the tray, the ends of the two connecting plates are fixedly connected with an air bag, the air bag is of a semicircular structure and attached to the inner side wall of the tray, a plurality of protrusions are fixedly installed on the surface of the air bag, one side of the top of the air bag is connected with an air pipe, and the air pipe extends out of the tray. The inflatable air bag and the protrusions connected with the inflatable air bag are arranged on the inner side wall of the tray, adjustment can be carried out according to the bellies of people with different weights, and therefore a patient can be stably supported in the middle of the tray, and later exercise training is facilitated.

The utility model discloses a myasthenia gravis rehabilitation exercise device which comprises a bottom plate, the middle position of the top of the bottom plate has a resistance exercise function, a grip is installed in the middle position of the top of the bottom plate, and supporting plates are arranged in the middle positions of the two sides of the end, close to the grip, of the top of the bottom plate. The tops of the two supporting plates are jointly provided with a seat cushion, and the inner bottoms of the two supporting plates are jointly provided with a rotating rod in a penetrating mode; through the cooperation of the work of a motor and the mutual engagement of a gear I and a gear II, the rotation work of a rotating disc can be realized, then the rotating disc drives a pedal sleeve plate to rotate so as to simulate the pedal operation of the bicycle, and through the design of the motor, the intelligent rotation work of the pedal can be realized, and a patient does not need to pedal the pedal in the later period; through the structural design of the component, a relatively serious patient in the later period can conveniently sit and stand for exercise work, and the function of exercising the legs of the patient is achieved by means of external force.

The invention relates to the technical field of motion trail tracking, in particular to a skeletal muscle motion trail tracking system for early screening of myasthenia gravis patients. Comprising the following steps: acquiring position coordinates and movement tracks of key skeletal muscle nodes; according to the instantaneous motion state fluctuation and curvature distribution of the motion trail, determining the abnormal degree of the muscle strength efficiency; the bending angle and time sequence electric signals of the target muscle with the synergistic effect on the muscle are obtained, and the synergistic breaking degree is determined according to the fluctuation correlation of the time sequence electric signals and the bending angles of the different muscles; and in combination with the muscle strength efficiency abnormal degree and the collaborative breaking degree, determining a motion trail abnormal coefficient, and performing tracking screening based on the motion trail abnormal coefficient. According to the method, irregular transition characteristics from a stable state to a tremor state of intermittent myasthenia can be effectively captured, and the sensitivity of early myasthenia screening is effectively improved.

The present invention provides a fusion protein for diagnosing myasthenia gravis, which detects AChR autoantibodies with high sensitivity and specificity, thus enabling rapid and accurate diagnosis of myasthenia gravis.

The invention belongs to the technical field of biological medicines, and discloses application of L-lactic acid in preparation of a medicine for promoting muscle injury repair and / or regeneration. The L-lactic acid can significantly promote proliferation and differentiation of muscle satellite cells, and helps to improve some external stimulation factors, such as myasthenia, amyotrophy, poor muscle coordination and other skeletal muscle dysfunction diseases caused by aging, injury, disuse or some degenerative diseases, such as poor prognosis. The invention provides a new diagnosis and treatment strategy and an effective molecular treatment target for treatment and prognosis of skeletal muscle dysfunction diseases. And on the other hand, the L-lactic acid provided by the invention is a small molecule metabolite, is relatively low in economic cost and relatively good in treatment effect, and has a considerable clinical application prospect.

The invention belongs to the technical field of cannula fixing devices, and discloses a cannula fixing device for myasthenia gravis rescue, which comprises an upper tooth socket and a lower tooth socket, the connecting seat is connected with the lower tooth socket, the upper tooth socket is connected with a sliding rod, the fixing plate slidably sleeves the sliding rod, the sliding rod is sleeved with a first spring, and the first spring is located between the fixing plate and the upper tooth socket; the fixing plate is detachably connected with the connecting seat through a buckle assembly; grooves are formed in the connecting seat and the fixing plate; the connecting base is rotationally connected with a rotating shaft which is connected with the upper tooth socket through a transmission assembly, and the connecting base is provided with a limiting assembly. The clamping cavity is defined by the fixing plate and the connecting base, fixing of an insertion pipe is achieved, dismounting and mounting are achieved through the buckles, and operation is convenient and fast; the opening degree of the upper tooth socket and the lower tooth socket is adjusted through the rotating shaft and the transmission assembly, so that oral care is facilitated; the fixing plate is matched with the sliding rod, the opening degree of the upper tooth socket and the lower tooth socket can be adjusted, the cannula can be fixed, and displacement or disengagement of the cannula is avoided.

The present invention relates to a novel complement C5-binding antagonist combination and a use thereof. The complement C5-binding antagonist combination according to the present invention comprises antagonists specifically binding to different domains of complement C5 and thus can significantly inhibit complement C5 activity, and therefore can be used for preventing or treating various complement-related diseases including myasthenia gravis, age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria.

Currently, there is no cure for myasthenia gravis (MG), and standard treatment focuses on symptom relief with the use of steroids or immunosuppressants, which have only temporary effects and are associated with serious side effects such as an increased risk of infection and death. [Solution] This application generally relates to compositions comprising tolerance-immunomodified particles encapsulating myasthenia gravis (MG)-related antigens, methods for treating MG using tolerance-immunomodified nanoparticles encapsulating MG-related antigens, and processes for preparing tolerance-immunomodified nanoparticles encapsulating MG antigens.

Provided herein are pharmaceutical compositions and approved products comprising an FcRn antagonist (e.g., efgartigimod, or a biosimilar version thereof) for subcutaneous administration and methods of use thereof for reducing the serum IgG level of a subject in need thereof (e.g., a subject having generalized myasthenia gravis (gMG)).